David Spellman
Net worth: 817 064 $ as of 2024-03-30
Profile
David A.
Spellman formerly worked at Vertex Pharmaceuticals, Inc., as VP-Commercial & International Finance, Mersana Therapeutics, Inc., as Chief Financial Officer from 2018 to 2019, Intarcia Therapeutics, Inc., as Chief Financial & Business Officer from 2019 to 2020, and Akebia Therapeutics, Inc., as Treasurer, Chief Financial & Accounting Officer from 2022 to 2023.
Mr. Spellman received his undergraduate degree from The Wharton School of the University of Pennsylvania.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-05-15 | 446,483 ( 0.21% ) | 817 064 $ | 2024-03-30 |
Former positions of David Spellman
| Companies | Position | End |
|---|---|---|
| AKEBIA THERAPEUTICS, INC. | Director of Finance/CFO | 2023-06-22 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Director of Finance/CFO | 2020-06-28 |
| MERSANA THERAPEUTICS, INC. | Director of Finance/CFO | 2019-06-29 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - |
Training of David Spellman
| The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| MERSANA THERAPEUTICS, INC. | Health Technology |
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- David Spellman
